Back to MRKView full pipeline
Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
2 competitors in Pulmonary Arterial Hypertension
View Full LandscapeDrug Information
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Regulatory Approvals
EMA8/22/2024
Winrevair
Winrevair, in combination with other pulmonary arterial hypertension (PAH) therapies, is indicated for the treatment of PAH in adult patients with WHO Functional Class (FC) II, III and IV.
OrphanPRIME
View on EMADrug Science
Mechanism of action & safety profile
Related Pipeline
MK-8748Phase 3
Diabetic Retinopathy
alendronate with cholecalciferolPhase 3
Osteoporosis
Simvastatin 20 mg dailyPhase 3
Cardiovascular Disease
EpinephrinePhase 3
Malignant Neoplasms of Male Genital Organs
9 valent human papillomavirus vaccine (Types 6, 11, 16, 18, 31, 33, 45, 52, 58)Phase 3
HPV Positive Oropharyngeal Squamous Cell Carcinoma
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts